Mirugen – Unlocking the Power of Retina Regeneration
Mirugen – Unlocking the Power of Retina Regeneration
Search results
Mirugen – Unlocking the Power of Retina Regeneration
Astena Theraputics' investigational gene therapy, ATSN-101, has shown promising long-term results in an early clinical trial for LCA1, a sever inherited retinal disease caused by mutations in the GUCY2D gene.
Gabriel Velichkova is in the second year of her Retina UK and Macular Society joint-funded PhD project at University College London (UCL) Institute of Ophthalmology.
Stephen Goulden MBE attended the first British Retinitis Pigmentosa Society (BRPS) meeting in 1977. He describes his involvement with the charity and with inherited sight loss as follows:
Since the publication of this newsletter our founder and honorary president Lynda Cantor MBE has passed away. We are all deeply saddened by this news.
The following questions are often asked by people contacting Retina UK.
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Including a gift to Retina UK in your Will is an incredibly special way to help our vital work continue into the future.
Our monthly e-Newsletter featuring the latest updates from Retina UK.